Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.
Krigstein M et al.
Annals of Laboratory Medicine, 2025
Exploring the Genetic Landscape of Primary Marginal Zone Lymphoma of the Urinary Bladder.
Balestri I et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Accurate affinity models for SH2 domains from peptide binding assays and free-energy regression.
Gagoski D et al.
Protein Science : a Publication of the Protein Society, 2025
MYD88 mutations in clonal hematopoiesis promote inflammation and hematopoietic stem cell expansion.
Yeung J et al.
Biorxiv : the Preprint Server for Biology, 2025
Sequence rules for a long SPOP-binding degron required for protein ubiquitylation.
Makhlouf L et al.
The Biochemical Journal, 2025
Accurate sequence-to-affinity models for SH2 domains from multi-round peptide binding assays coupled with free-energy regression.
Gagoski D et al.
Biorxiv : the Preprint Server for Biology, 2025
Sphinganine recruits TLR4 adaptors in macrophages and promotes inflammation in murine models of sepsis and melanoma.
Hering M et al.
Nature Communications, 2024
An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.
Flümann R et al.
Blood Advances, 2024
TP53 mutation is a high-risk factor for Richter's syndrome based on circulating tumor DNA.
Park HS et al.
Blood Research, 2023
Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis.
Stacey SN et al.
Nature Genetics, 2023
Asian variant intravascular large B-cell lymphoma with highly suspected central nervous system involvement: A case report.
Lee YP et al.
World Journal of Clinical Cases, 2023
Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.
Scheich S et al.
Cancer Discovery, 2023
The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
Elbaz O et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas.
Venturutti L et al.
Cancer Discovery, 2023
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Flümann R et al.
Blood Cancer Discovery, 2023
Diagnostic value of genetic mutation analysis and mutation profiling of cell-free DNA in intraocular fluid for vitreoretinal lymphoma.
Chen X et al.
Cancer Communications (london, England), 2022
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Ma MCJ et al.
Haematologica, 2022
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.
Rodriguez S et al.
Science Advances, 2022
MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.
Chen R et al.
Therapeutic Advances in Hematology, 2022
Heterologous Expression and Assembly of Human TLR Signaling Components in Saccharomyces cerevisiae.
Coronas-Serna JM et al.
Biomolecules, 2021
Detection of c.755T>C; p.L265P/c.751C>T;p.264R/* compound heterozygous MYD88 mutation in a case of Waldenstrom macroglobulinemia.
Gautam A et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2021
MyD88 TIR domain higher-order assembly interactions revealed by microcrystal electron diffraction and serial femtosecond crystallography.
Clabbers MTB et al.
Nature Communications, 2021
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2.
Singh K et al.
Diagnostics (basel, Switzerland), 2021
MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.
Yu X et al.
Blood, 2021
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.
Flümann R et al.
Blood Cancer Discovery, 2021
Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models.
Mossadegh-Keller N et al.
Frontiers in Immunology, 2021
Mouse Models of Germinal Center Derived B-Cell Lymphomas.
Meyer SN et al.
Frontiers in Immunology, 2021
Lymphoplasmacytic lymphoma in a patient with Birt-Hogg-Dubé syndrome.
Kurata K et al.
International Journal of Hematology, 2020
Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
Zanwar S et al.
Current Hematologic Malignancy Reports, 2020
B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.
Schmidt K et al.
Frontiers in Immunology, 2020
Role of self-organising myddosome oligomers in inflammatory signalling by Toll-like receptors.
Gay NJ
Bmc Biology, 2019
Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber ANR et al.
Cancer Immunology, Immunotherapy : Cii, 2018
Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma.
Wenzl K et al.
Blood Cancer Journal, 2018
Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.
Wang JQ et al.
The Journal of Experimental Medicine, 2017
Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G et al.
European Journal of Haematology, 2016
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Knittel G et al.
Blood, 2016
Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.
Wang JQ et al.
The Journal of Experimental Medicine, 2014
Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells.
Loiarro M et al.
The Journal of Biological Chemistry, 2013
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Morin RD et al.
Nature, 2011